首页 › 基金 › Parkman Healthcare Partners LLC › TARS
Parkman Healthcare Partners LLC 对 TARS 的持仓历史
TARSUS PHARMACEUTICALS INC · 医疗保健
Parkman Healthcare Partners LLC 在 Q3 2026 的 13F 申报中披露持有 TARS(TARSUS PHARMACEUTICALS INC)213,395 股,市值约 US$16.8M,约占其申报组合的 1.51%,在其申报持仓中市值排名第 22 位。 Parkman Healthcare Partners LLC 最近 2 个申报季度中有 2 个季度披露了 TARS 持仓,最早可追溯至 Q2 2026。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Parkman Healthcare Partners LLC 对 TARS 的持仓演变
Parkman Healthcare Partners LLC 于 Q2 2026 首次披露 TARS 持仓:150,000 股(约 US$9.4M)。 该持仓在 Q3 2026 达到峰值 213,395 股,市值约 US$16.8M。 在 2 次申报中,Parkman Healthcare Partners LLC 1 次增持、0 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 213,395 股、市值约 US$16.8M,环比增持 63,395 股。。 持仓曾出现大幅变动:Q3 2026 增持约 42% (随后一个季度股价上涨 2%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 150.00K | $9.44M | 新进 |
| Q3 2026 | 213.40K | $16.77M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 TARS 与 13F 数据
TARS(TARSUS PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 43 只申报持有 TARS,申报仓位最大的包括:Deep Track Capital, LP (US$299.3M), RTW INVESTMENTS, LP (US$273.9M), Paradigm Biocapital Advisors LP (US$180.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 TARS 的基金
- Deep Track Capital, LP 3.81M 股 · $299.25M · Q3 2026
- RTW INVESTMENTS, LP 3.48M 股 · $273.88M · Q3 2026
- Paradigm Biocapital Advisors LP 2.30M 股 · $180.91M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.57M 股 · $98.71M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 1.10M 股 · $86.17M · Q3 2026
- Vestal Point Capital, LP 1.05M 股 · $66.09M · Q2 2026
- Frazier Life Sciences Management, L.P. 728.64K 股 · $45.86M · Q2 2026
- TCG Crossover Management, LLC 388.16K 股 · $30.51M · Q3 2026
- Rock Springs Capital Management LP 285.12K 股 · $22.41M · Q3 2026
更多关于 Parkman Healthcare Partners LLC
常见问题
How long has Parkman Healthcare Partners LLC held TARS?
Parkman Healthcare Partners LLC has disclosed TARS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Parkman Healthcare Partners LLC's current position in TARS?
As of Q3 2026, Parkman Healthcare Partners LLC holds 213.40K shares of TARS (TARSUS PHARMACEUTICALS INC), valued at $16.77M, representing 1.51% of its reported portfolio and ranking #22.
Has Parkman Healthcare Partners LLC been buying or selling TARS?
In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC increased its position in TARS. The position peaked in Q3 2026 at 213.40K shares.
Which other funds hold TARS?
Other major institutional holders of TARS include Deep Track Capital, LP, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.